Sanofi Genzyme BioVentures

Sanofi Genzyme BioVentures is the corporate venture capital arm of Sanofi, focusing on early-stage investments in biotechnology and life sciences companies. The firm seeks to identify and support innovative companies that align with Sanofi's strategic interests, aiming to enhance the company's pipeline and foster external innovation. The investment strategy emphasizes sectors such as biotechnology, pharmaceuticals, healthcare, medical devices, diagnostics, and genomics. Sanofi Genzyme BioVentures invests across various stages, including seed, early stage, Series A, Series B, growth, late stage, and pre-IPO, with investment sizes ranging from $1 million to $50 million. The geographical focus spans multiple countries, including the United States, France, Germany, Italy, Spain, the United Kingdom, China, Japan, India, Brazil, Mexico, Canada, Australia, South Korea, Russia, South Africa, Saudi Arabia, Turkey, Argentina, and Chile. By leveraging Sanofi's global presence and expertise, Sanofi Genzyme BioVentures aims to accelerate the development of transformative therapies and address unmet medical needs worldwide. The firm's portfolio includes companies across various therapeutic areas, reflecting its commitment to advancing healthcare through strategic partnerships and investments.

Innovative biotechnology and life sciences companies, Alignment with Sanofi's strategic interests, Early-stage companies with promising new products, Potential future pipeline candidates for Sanofi